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DOI 10.1186/s12889-017-4639-3RESEARCH ARTICLE Open AccessEvaluation of the colorectal cancer
screening Programme in the Basque
Country (Spain) and its effectiveness based
on the Miscan-colon model
I. Idigoras1,2*, A. Arrospide3,4,5, I. Portillo1,2, E. Arana-Arri2, L. Martínez-Indart2, J. Mar3,4,5, H. J. de Koning6, R. Lastra7,
M. Soto-Gordoa3,4,5, M. van der Meulen6 and I. Lansdorp-Vogelaar6Abstract: The population-based Basque Colorectal Cancer (CRC) Screening Programme started in 2009 with a
biennial immunochemical quantitative test (FIT) biennial and colonoscopy under sedation in positive cases. The
population target of 586,700 residents was from 50 to 69 years old and the total coverage was reached at the
beginning of 2014. The aim of our study was to determine possible scenarios in terms of incidence, mortality and
reduction of Life-years-Lost (L-y-L) in the medium and long term of CRC.
Methods: Invitations were sent out by the Programme from 2009 to 2014, with combined organizational strategies.
Simulation was done by MISCAN-colon (Microsimulation Screening Analysis) over 30 years comparing the results of
screening vs no-screening, taking the population-based Cancer Registry into account. Lifetime population and real data
from the Programme were used from 2008 to 2012. The model was run differentially for men and women.
Results: 924,416 invitations were sent out from 2009 to 2014. The average participation rate was 68.4%, CRC detection
rate was 3.4% and the Advanced Adenoma detection rate was 24.0‰, with differences observed in sex and age. Future
scenarios showed a higher decrease of incidence (17.2% vs 14.7%), mortality (28.1% vs 22.4%) and L-y-L (22.6% vs 18.4%)
in men than women in 2030.
Conclusions: The Basque Country CRC Programme results are aligned to its strategy and comparable to other
programmes. MISCAN model was found to be a useful tool to predict the benefits of the programme in the future. The
effectiveness of the Programme has not been formally established as case control studies are required to determine long
term benefits from the screening strategy.
Keywords: Colorectal cancer, Early detection of cancer, Incidence, Mortality, Life year lost, Effectiveness, Programme
evaluationBackground
Colorectal cancer (CRC) is the third leading cancer-
related cause of death in developed countries. The
European Union (EU) has the highest incident rate and
ranks second in mortality of both sexs, with 446,000
newly-diagnosed cases each year and a mortality rate
estimated in 214,000 cases annually [1].* Correspondence: isabel.idigorasrubio@osakidetza.eus
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regions of Spain, it is also the most frequent type of
cancer. In 2008, 642 new cases and 286 deaths in
women and 1227 new cases and 504 deaths in men were
registered [2].
Different screening strategies have been proposed to
reduce the CRC incidence and mortality, by means of
different diagnostic tests. Previously, evidence of the
reduction in mortality using the guaiac test (gFOBT) for
population-based screening, showed a reduction in mor-
tality of 10–16% [3–5].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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pact on mortality of a CRC screening programme using
immunochemical quantitative tests (FIT), several clinical
trials show that these tests achieve a higher neoplasia
detection rate and higher positive predictive values
(PPV) than the gFOBT [6–8]. In fact, the European
guidelines of screening for CRC (2010) [9] recom-
mended these tests for population-based screening
programmes.
A recent study published by Zorzi et al. [10] estab-
lished that the screening programmes based on FIT
were associated with a reduction of up to 22% in
CRC mortality.
In accordance with the European recommendation
(2003) [11] and the National Health System’s strategy
against cancer (NHS) [12, 13], in 2008 the Basque
Government approved the implementation of a regional
population-based screening programme for CRC. The
programme was aimed at men and women between 50
and 69 years old, using one sample biennially of FIT and
a colonoscopy under sedation as a diagnostic confirm-
ation in positive cases. The programme started in 2009,
reaching almost the whole target population (approxi-
mately 586,700 people) at the beginning of 2014. The
main results found in the first period showed a high
participation rate, as well as high adenoma and CRC
detection rates [14, 15].
In order to measure the effectiveness of the
Programme and its current strategy in comparison to
no-screening, the MISCAN-colon tool [16], widely and
internationally validated, was chosen.
The objectives of this study were to predict future
scenarios and outcomes for the Basque population and
to determine the epidemiological benefits of the screen-
ing programme in terms of incidence, mortality and
years of life lost (L-y-L).
This kind of evaluation could be useful to those coun-
tries rolling out screening programmes in order to
implement actions and guarantee their continuation.
Methods
The Basque Country CRC Screening Programme is
population-based and its main strategy was based on: A)
a coordinating office, including clinical epidemiologists
and statisticians, to plan, organize, manage and evaluate
the Programme; B) all residents from 50 to 69 years
were invited biennially, taking into account the health
centers and referral hospitals, in order to adjust the posi-
tivity expected and colonoscopy capacity; C) prior to the
invitation, the coordinating office selected the target
population and linked the database to the Basque popu-
lation cancer and medical procedures registries to
exclude individuals with a previously-diagnosed CRC,
terminal illness and reported colonoscopy in the pastfive years; D) training and involvement of the primary
care staff; E) individualized posted invitations providing
information about the Programme. After 4–6 weeks
from the initial invitation, the kit (FIT) was sent along
with instructions and individualized bar code. This bar
code allowed the sample and person to be identified
when processing the result. Samples were collected at
primary health centers and processed in centralized pub-
lic laboratories under strict and total quality manage-
ment systems; F) all results were reviewed by primary
care physicians and introduced in “ad hoc” CRC preven-
tion software. Letters were posted with results. In posi-
tive cases, participants were recommended to visit their
general gractitioner, who referred them to the hospital
for colonoscopy. G) Colonoscopies (diagnostic and
therapeutic if needed) were performed in public hospi-
tals under deep sedation by specialists. H) All cases were
followed-up with close coordination between primary
care and specialized units; I) every case was coded by
the coordinating office staff following standard EU
guidelines and Spanish network consensus [17]; J)
interval cancer and complications were identified and
monitored by registries linkage before invitation and
after colonoscopy performance. The programme is
identified in (Fig. 1).
This study was approved by the Basque Country’s Eth-
ics Committee.
The FIT used was OC-Sensor Micro (Eiken Chemical
Co. Ltd., Toyo, Japan) (from 2009 until now) and FOB-
Gold (Sentinel CH. SpA, Milan, Italy) 2009–2010 in
15,000 invitations). The faecal-Haemoglobin (f-Hb) cut-
off was 20 μg Hb/g faeces for both sexs. The decision to
use one single sample of FIT and the biennial period
between invitations followed the recommendations of
Levis and van Rossum [18, 19], in order to reach the
highest participation rate with the best balance between
sensitivity and specificity.
A satisfactory colonoscopy was considered if the
caecum was reached and the quality of colonic cleansing
was coded higher than 6 in all segments measured by
the Boston Bowel Preparation Scale (BBPS). The American
Association’s classification was used for CRC and stages
[20]. Accordingly, the results of the colonoscopy were
coded and follow-up recommendations assigned to each
one as: 1) Normal/No adenomatous pathology and will be
invited to perform a screening test within 10 years; 2) Hy-
perplastic polyps and will be invited to perform a screening
test within 10 years; 3) Low risk adenomas and will be in-
vited to perform a test within 5 years 4) Intermediate risk
adenomas and remain on colonoscopy surveillance within
3 years; 5) High risk adenomas and remain on colonoscopy
surveillance within 1 year; 7) Cancer, neoplasia which
infiltrates the submucosa layer ≥pT1) followed by the
hospital specialists.
Fig. 1 Work flow of the Basque Colorectal Cancer Screening Programme
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order to describe the main benefits of the Programme.
For the simulation model, the result of the period of
2009–2012 was used for the Basque Country’s inhabi-
tants, and the results obtained from the invitation during
2013–2014 were used to check and contrast the results
obtained by the simulation on the MISCAN-colon.
MISCAN model adaptation
The MISCAN-colon was used to estimate the results of
the screening strategy of biennial FIT from 50 to
69 year-olds in the Basque Country. The MISCAN
model and the parameter’s sources were fully explained
in previous publications [15, 21] and in the standardized
model profile of the Cancer Intervention and Screening
Network (CISNET) [22]. This model simulates the rele-
vant life histories of a large population of individuals
from birth to death. CRC arises in this population in ac-
cordance with the adenoma-carcinoma sequence [23].
MISCAN simulated the Basque population in 2008
with its age-structure divided into different strata de-
pending on the age at which they were invited to theProgramme for the first time (or never invited if they
were over 70 in 2008). Given the significant differences
in the epidemiology of CRC between men and women,
MISCAN model was run separately for each sex. The
validation took into account the stage and localization of
CRC in the period of 2005–2008 and the adenoma
prevalence calculated for the Basque population using a
sample of the COLONPREV study [24].
After reproducing the natural history without
screening, the model reproduced the behavior of CRC
in a screening scenario by considering the impact of
removing adenomas and anticipating CRC stage at
diagnosis. Those consequences were translated into
quality-adjusted life years gained and treatment costs
avoided [25].
In this analysis, the MISCAN-colon model was ad-
justed to represent the situation of the Basque Country:
birth and lifetables and CRC risk and survival from the
Cancer Population Register and the Basque Institute of
Statistics (EUSTAT) [26]. For the Basque Country, the
MISCAN-colon modelling has been adapted to regard
the findings of adenomatous lesions, in adenomas
Idigoras et al. BMC Public Health  (2018) 18:78 Page 4 of 12smaller and bigger than 10 mm. The projection has been
done for 30 years from the implementation of the
screening programme. For the prevalence of adenomas,
the COLONPREV study and other studies were consid-
ered [22, 27, 28].
Results
Outcomes of the population-based Basque CRC screening
Programme
924,416 individuals were invited (2009–2014), with an
average participation rate of 68.4% representing an in-
cremental increase over the study period (58.1% -
70.3%). Trends of participation increased 2.2% yearly
(95% CI 2.0–2.4; p < 0.001) with 91.8% being regular
participants in the second round and 95.8% in the third
round. The adherence to colonoscopy after FIT positive
result has been higher than 92% in all years of the study.
The Advanced Adenoma (AA) detection rate was 23.9‰
and CRC detection rate was 3.4‰. In he 66.4% of CRC
cases, the detection was registered in Stage I-II. Indica-
tors by round and sex are detailed in Table 1.
Comparing the results obtained on the actual screen-
ing scenario with the observed data for invitations,
participation rate, positive screen tests and detection
rates, we can conclude that the model reproduced well
the observed data (Fig. 2).
In Table 2, the future projections were predicted for
men and women regarding future invitations, participa-
tion, diagnostic/surveillance colonoscopies and detected
lesions in different years, the last projection being done
in 2038. Observed differences between men and women
were noticed in participation, as well as in detected le-
sions. A trend towards stabilization was observed in all
parameters of the projection for 2020 and onwards, but
the surveillance colonoscopies seemed to stabilize ten
years later.
In Fig. 3, a decrease in the CRC incidence was shown
after 30 years of screening, greater in men (17.2%) than
in women (14.7%). In both sexs, ten years after the
Programme started, a decrease was found in the number
of cases of CRC. Considering both sexs, the average de-
crease found was 16.3%.
Regarding the reduction in mortality for this same pro-
jection, the decrease for men was 28.1% and 22.4% for
women, with an upward trend from the beginning of the
Programme, the average decrease being 26.1% (Fig. 4).
The reduction of Life-years-Lost was also greater in
men than in women (22.6% vs 18.4%) with an upward
trend from the beginning of the Programme and an
average for both sexs of 21% (Fig. 5).
Discussion
The strategy of the CRC Screening Programme in the
Basque Country has been implemented according to therecommendations of the EU [9], taking into account the
target group and professionals when considering its
implementation.
The main results of the Programme showed a high
participation rate in both sexs in the three rounds from
2009 to 2014, possibly related to the implemented strat-
egy, according to McGregor et al. [29], who demon-
strated a relation to participation in both sexs (men OR
5.0; 95% CI 2.9 to 8.3 and women OR 3.8; 95% CI 2.3 to
6.5). Tinmouth et al. [30] also showed the importance of
the family physician when providing information about
the programme’s role after Programme invitation. How-
ever, Van Roosbroeck et al. [31] demonstrated a higher
participation rate related to the type of invitation,
higher in shipping kits to a participant’s home than
when delivered by the rimary care physician (OR 2.96
95% CI 2.78 to 3.14). Combined strategies could be
efficient to achieve a higher participation rate. Also,
quality assurance plays an important role (Von Karsa
et al., 2013) [32].
The f-Hb cut-off point chosen in FIT has generated a
lot of discussion in terms of the number of colonos-
copies to be performed, which was an initial limitation
to the total extension of the Programme. However, it has
not been modified in terms of cut-off age to deal with
the management of positive cases, but that should be
taken into account in successive rounds, according to
van Rossum 2009 [33].
The lesion detection rate analysis reported a high
trend in the first round with a significant decrease in
successive rounds, following the same pattern as the
positive FIT test. The largest decline occurred primarily
in men and in AA. Denters et al. [34] found a significant
decrease in PPV for AN (Advanced Neoplasia) between
the first and the second round of 55% (132/239) to 44%
(112/252), (p = 0.017). The PPV for CRC was 8% (20/
239) in the first round vs 4% (9/252) in the second
round (p = 0.024).
CRC detected by screening were in early stages (I-II)
in 66.4%, contrasting with previous data (45.8%)
(Departamento de Sanidad y Consumo et al., 2010) [2].
In the Basque Country Programme, considering its
rapid extension and its high participation rate and le-
sions detected, a positive medium-to -term impact could
be expected. This impact was suggested by Zorzi et al.
[10] who found a better impact related to geographic
locality and the implementation of screening, with
higher reductions in mortality in women (RR=0.64; 95%
CI = 0.51–0.80) than in men (RR 0.87 95% CI 0.73–
1.04), but with significant results in all cases.
The choice of the MISCAN-colon model to simulate
the impact of the Programme, both mid and long term,
has given us the opportunity to establish a future sce-
nario based on real data, regarding the incidence and
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Fig. 2 Observed and simulated invitations and participants by sex 2009–2014
Idigoras et al. BMC Public Health  (2018) 18:78 Page 6 of 12mortality before screening as well as the Programme’s
results after its start in 2009. One outstanding feature
of this method was being able to count on
internationally-renowned cancer registers, which make
the study of the effectiveness in screening feasible
(Anttila et al., 2015) [35].
In this respect, the incidence and mortality rates in the
Basque Country are different than in other European
regions [36]. When compared with European Population
Registers, the Basque Country showed a higher inci-
dence rate in men and an average rate in women com-
pared to the Netherlands, Italy, and Scotland and North
Thames in the UK. The mortality rate in men was also
higher. However, these incidence and mortality rates
showed an intermediate position for women [37].
The simulation applied to sexs offered a wider vision
of CRC, which was not reflected in a majority of re-
search, and which was, however, important to calculate
the impact of screening programmes. In the current
study, the impact of dealing with different population
groups was evident, not only regarding the incidence
and mortality of CRC, but also how both sexs behavedin participation, positive test rates and the rate of de-
tected lesions. Hence, the programme’s impact was
shown to be greater in men than in women, but unfortu-
nately men participated less than women.
After a 30-year projection, and with participation rates
adjusted to the results of the Programme, the decrease
in incidence and mortality found seems compatible with
what is reflected in current literature, although it is diffi-
cult to compare results, due to the dissimilarities in con-
text, including simulations of 100% participation and
short or indeterminate follow-up periods. However, the
quality of simulation and the adaptation of parameters
proved successful according to the real data provided by
the Programme.
The reduction in incidence would start in the first ten
years of the Programme’s implementation with signifi-
cant increases over time. As other authors have stated,
CRC screening not only decreases mortality, but it pre-
vents new cases Ventura et al. [38], which contributes to
minimizing the burden of the disease in the future. On
the basis of higher incidence rates, the mid-to-long term
impact could represent an important reduction in both
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Fig. 3 Incidence decreasing for men and women in 30 years
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et al. [39] who found a significantly lower mortality rate
in screening in 5 years compared to non-screening or
pre-screening colorectal cancer patients (19% vs 37%
and 41%; p < 0.001).
In this sense, the L-y-L for both sexs is very high and
provided an important tool for regional and national
authorities, as well as policy makers, to invest and supportFig. 4 Mortality decreasing by sex in 30 yearsthese types of programmes, taking into account
organization and quality indicators. That recommendation
was suggested by van Hees et al., [40] from the
Netherlands.
Comparisons between programmes are difficult, as
was suggested by Klabunde et al. [41], who found a
range of invitation coverage from 30 to 100% and
coverage by the screening Programme from 7 to 67.7%,
Fig. 5 Decreasing in Life years lost by sex in 30 years
Idigoras et al. BMC Public Health  (2018) 18:78 Page 10 of 12overall participation rate from 7 to 67.7%, and first invi-
tation participation from 7 to 64.3%. These differences
could be minimized by implementing different measures
to increase coverage and catchment in order to
maximize the equality of access and the impact on pub-
lic health recommended by Senore et al. [42]. One of the
limitations of this study is that the classification of the
risk of those with removed adenoma, due to the use of
MISCAN model, had to be done based only on the size
of the lesion, so those identified with other characteris-
tics such as number of adenomas or the grade of dyspla-
sia, had to be proportionally distributed [43].
Another limitation is the uncertainty in estimated ad-
enoma prevalence, which was considerably higher than
previously observed in other studies included, to build
the MISCAN-colon model. This is, however, consistent
with the fact that the study programme has a high par-
ticipation rate that has been maintained throughout the
study period and has not declined in new participants.
Based on the robustness of the model, this maintained
rate supports the prediction.
An important strength of our study is a well validated
model based on several years of data from a high
participation-rate population-based programme, directly
reported by The Basque Country data and the concord-
ant results observed.
In the future, some findings in FIT performance charac-
teristics, with respect to repeating screening rounds, would
be taken into account in order to increase efficiency (van
der Meulen et al., 2016) [44]. NowaCurrently, we still havedifficulty comparing data from different models, relatedd to
a lack of randomized control trials on the effectiveness of
FIT, and a lack of data on participation in surveillance and
uncertainty in adenoma prevalence. Consequently, there is
a need to carry out prospective cohort studies to evaluate
the impact of the effectiveness of these programmes within
the context of implementation and considering all the pos-
sible parameters and their influence.
The results obtained within this research are in line
with previously published studies on cost-effectiveness
analysis [45].
Nevertheless, the results of the projections offer a
rather modest reduction of the main parameters mea-
sured. These projections indicate a need to consider
how to improve the efficiency of currently implemented
strategies. This incudes analyzing the possibility of
implementing complementary or improved strategies
such as the introduction of algorithms of risks, differen-
tiating among men and women, familiar susceptibility
(detected lesions subgroup analysis) or adjusting the cut
off levels of the current test. Primary care physicians and
authorities are key in maintaining the programme as it is
described here. Primary care physicians are central to
informing the population about the benefits of being
screened and, thus, maintaining the high participation
rates. Authorities are important in ensuring the level of
investment in order to guarantee that no delays in the
subsequent diagnostics and managing processes are gen-
erated. The latter is crucial not just from the perspective
of the programme itself and its intermediate results
Idigoras et al. BMC Public Health  (2018) 18:78 Page 11 of 12(detected lesions as early as possible), but to improve
the final outcomes on life expectancy and quality of life.
Conclusions
The Basque Country CRC Programme results are
aligned to its strategy and comparable to other pro-
grammes. MISCAN model was found to be a useful tool
to predict the benefits of the programme in the future.
According to the parameters of simulation of MISCAN-
colon and by means of the early obtained data of the
Programme, the screening seems to be an effective strat-
egy in order to reduce the incidence, mortality and L-y-
L. These results provide further evidence on the
efficiency of population-based CRC programmes. These
data support the continuity of the programme and show
the need for further improvements in the selected
strategy to increase its efficiency.
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